-transparent.png){kind=logo}
C1- and C3-methyl-substituted derivatives of 7-hydroxy-2-(di-n-propylamino)tetralin: activities at central dopamine receptors. 1987
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
Department of Organic Pharmaceutical Chemistry, Biomedical Center, University of Uppsala, Sweden.
C1- and C3-methyl-substituted derivatives of the potent dopamine (DA) receptor agonist 7-hydroxy-2-(di-n-propylamino)tetralin (7-OH-DPAT) have been synthesized, and their conformational preferences have been studied by use of NMR spectroscopy, X-ray crystallography, and molecular mechanics (MMP2) calculations. The compounds were tested for activity at central DA receptors, by use of biochemical and behavioral tests in rats. (1S,2R)-7-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin [(+)-10] was demonstrated to be sevenfold less potent than (2R)-7-OH-DPAT as a DA receptor agonist. The other new compounds were of lower potency or inactive.
Related Publications
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
June 1988,
Journal of medicinal chemistry,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
November 1987,
European journal of pharmacology,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
January 1996,
The Journal of pharmacy and pharmacology,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
July 2008,
British journal of pharmacology,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
January 1991,
Neuroscience letters,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
April 1988,
Journal of medicinal chemistry,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
January 2018,
Andrologia,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
January 1995,
Xenobiotica; the fate of foreign compounds in biological systems,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
January 1984,
Journal of neural transmission,
A M Johansson, and
J L Nilsson, and
A Karlén, and
U Hacksell, and
D Sanchez, and
K Svensson, and
S Hjorth, and
A Carlsson, and
S Sundell, and
L Kenne
March 1994,
Neurochemical research,
